Skip to content

Rhomboid Intercostal and Subserratus Plane Block vs Erector Spinae Plane Block in Video-Assisted Thoracoscopic Surgery

Comparison of the Efficacy of Rhomboid Intercostal and Subserratus Plane Block (RISS) Versus Erector Spinae Plane (ESP) Blocks in Video-Assisted Thoracoscopic Surgery (VATS) for Postoperative Pain Management and Respiratory Function

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07011069
Enrollment
90
Registered
2025-06-08
Start date
2024-11-15
Completion date
2026-12-31
Last updated
2025-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Video Assisted Thoracoscopic Surgery, Regional Block for Pain Control, Regional Blocks, Pulmonary Functions

Brief summary

To compare the rhomboid intercostal subserratus plane block with the erector spinae plane block regarding their analgesic efficacy and effects on respiratory function for patients undergoing video-assisted thoracoscopic surgery.

Detailed description

Video-assisted thoracoscopic surgery (VATS) can be very painful and may lead to complications such as prolonged stays in intensive care, thromboembolic complications due to lack of early mobilization, chronic acute pain, and delirium if adequate analgesia is not provided. Therefore, using thoracic epidural, paravertebral, or regional blocks as part of multimodal analgesia is recommended to provide effective pain relief. This study aims to compare the effects of the erector spinae plane block (ESP) and rhomboid intercostal subserratus plane block (RISS) on postoperative analgesia and the improvement of respiratory parameters in patients undergoing VATS. The primary objective is to evaluate total analgesic consumption in the first 24 hours postoperatively. Secondary objectives include assessing active and dynamic pain scores, triflow performance, complications, and the length of hospital stays.

Interventions

ESP blocks are performed for patients undergoing VATS.

PROCEDURERISS block group

RISS blocks are performed for patients undergoing VATS.

Sponsors

Bursa City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who will undergo VATS * Who agrees to participate * American Society of Anesthesiologists (ASA) physical status I, II, and III * Elective surgery * Age between 18 and 80 years

Exclusion criteria

* Local anesthetic allergy * Who disagrees to participate * ASA physical status IV and V * Emergency surgery * Hemorrhagic disease * Thoracic vertebrae deformity * Thoracic vertebrae surgery

Design outcomes

Primary

MeasureTime frameDescription
Opioid consumptionPostoperative first 24 hours.Total opioid consumption within the first 24 hours in the postoperative period.

Secondary

MeasureTime frameDescription
Dynamic pain scorePostoperative first 24 hours.Postoperative pain scores during coughing and deep breathing are measured on a 10 cm scale, where 0 indicates no pain and 10 indicates the worst pain ever.
Resting pain scorePostoperative first 24 hours.Postoperative pain scores during rest are measured on a 10 cm scale, where 0 indicates no pain and 10 indicates the worst pain ever.
Pulmonary functionsPostoperative first 24 hours.Pulmonary functions are assessed using Triflow performance. Postoperative Triflow numbers (whether 1, 2, or 3 balls can be raised) for the patients are recorded.
ComplicationsThrough study completion, an average of 1 yearComplications regarding regional blocks and surgery (such as hematoma, pulmonary complications) are recorded.
Hospital stay timePerioperativelyThe length of hospital stay is recorded.

Countries

Turkey (Türkiye)

Contacts

Primary ContactHande Gurbuz, Assoc Prof, MD, PhD
handegrbz@gmail.com+905336515650
Backup ContactYusuf Alan, MD
dryusufalan@gmail.com+90 539 621 09 77

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026